Spruce Biosciences to Present Posters at 2024 Endocrine Society Meeting

Spruce Biosciences, Inc. (Nasdaq: SPRB), a biopharmaceutical company specializing in the development and commercialization of innovative treatments for rare endocrine disorders, has announced the acceptance of three abstracts for presentation at the 106th Annual Meeting of the Endocrine Society (ENDO 2024). The event is scheduled to take place from June 1 to June 4, 2024, in Boston.

One of the key highlights will be a poster presentation featuring the final results from Spruce Biosciences' Phase 2 POWER study. This research explores the efficacy and safety of tildacerfont in treating polycystic ovary syndrome (PCOS). The study specifically targets adult patients with PCOS who have elevated adrenal androgens. The presentation, titled "A Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of Tildacerfont in Adult Subjects with Polycystic Ovary Syndrome (PCOS) and Elevated Adrenal Androgens," will be showcased on June 2, 2024, from 12:00 to 1:30 p.m. ET. The session will be presented by Dr. Ricardo Azziz, a Professor of Obstetrics and Gynecology at the University of Alabama at Birmingham School of Medicine.

In addition to the findings on tildacerfont, Spruce Biosciences will present research on congenital adrenal hyperplasia (CAH) and the complications associated with standard care treatments for this condition. The second presentation, titled "Impact of Geography and Insurance on Healthcare Utilization Preferences of Individuals with Congenital Adrenal Hyperplasia," will delve into how factors like geography and insurance affect healthcare preferences in CAH patients. This session will take place on June 1, 2024, from 12:15 to 1:45 p.m. ET and will be led by Dr. Prasanth Surampudi, an Associate Professor of Endocrinology, Diabetes, and Metabolism at the U.C. Davis School of Medicine.

The third presentation, titled "The Treatment May Be Worse Than the Disease: The Real-World Clinical Burden of Disease and Treatment in Congenital Adrenal Hyperplasia," will also be part of the ENDO 2024 program on June 1, 2024, from 12:15 to 1:45 p.m. ET. This research will be presented by Dr. Wenyu Huang, an Associate Professor at Northwestern University Feinberg School of Medicine, and Dr. Amir Hamrahian, an Associate Professor at John Hopkins University. The presentation will provide insights into the real-world clinical burdens and challenges of treating CAH.

Spruce Biosciences is committed to addressing significant unmet medical needs in the field of rare endocrine disorders. Their wholly-owned product candidate, tildacerfont, aims to become the first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH) and other endocrine disorders. The company continues to push forward with its research and development efforts to bring effective treatments to patients in need.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!